XML 29 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
Related Party Transactions (Details) (USD $)
1 Months Ended 0 Months Ended 3 Months Ended 9 Months Ended 0 Months Ended 0 Months Ended
May 31, 2014
Payment
Sep. 30, 2014
Dec. 31, 2013
Mar. 24, 2010
GeneOne Life Sciences [Member]
Sep. 30, 2014
GeneOne Life Sciences [Member]
Sep. 30, 2013
GeneOne Life Sciences [Member]
Sep. 30, 2014
GeneOne Life Sciences [Member]
Sep. 30, 2013
GeneOne Life Sciences [Member]
Dec. 31, 2013
GeneOne Life Sciences [Member]
Mar. 24, 2010
GeneOne Life Sciences [Member]
Dec. 31, 2013
OncoSec [Member]
Sep. 28, 2011
OncoSec [Member]
First warrant [Member]
Sep. 28, 2011
OncoSec [Member]
First warrant [Member]
Mar. 24, 2012
OncoSec [Member]
Second warrant [Member]
Mar. 24, 2012
OncoSec [Member]
Second warrant [Member]
Related-Party Transactions (Textual) [Abstract]                              
Payment received for license granted       $ 3,000,000                      
Deferred revenue from affiliated entity                   3,000,000          
Period over which deferred revenue from affiliated entity will be recognized in years       8 years                      
Revenue from related parties         113,000 106,000 367,000 319,000              
Operating expenses related to affiliated entity         413,000 402,000 4,100,000 960,000              
Other Assets, Noncurrent   552,459 402,075   338,000   338,000   231,000            
Payments received from affiliate                     3,000,000        
Common stock purchase warrant                         1,000,000   3,000,000
Term of the warrants in years                       5 years   5 years  
Exercise price of a five-year warrant                       $ 1.20   $ 1.00  
Subsidiary ownership percentage by parent 91.00%                            
Receivable from sale of intangible assets 2,000,000                            
Number of future payments to be received from sale of intangible assets 2                            
Future payments to be received from sale of intangible assets 1,000,000                            
Equity ownership percentage after transaction 20.00%                            
Maximum amount of additional equity fundraising $ 10,000,000